<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081051</url>
  </required_header>
  <id_info>
    <org_study_id>AM 001</org_study_id>
    <nct_id>NCT04081051</nct_id>
  </id_info>
  <brief_title>Advancing Access to Diagnostic Innovation Essential for UHC and AMR Prevention</brief_title>
  <acronym>Accelerator</acronym>
  <official_title>Impact of Improved Diagnostic Tools, Training and Communication on Acute Fever Case Management and Antibiotic Prescriptions for Children and Adolescents Presenting at Outpatient Facilities in Lower &amp; Middle-Income Countries.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indian Council of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>WHO, Special Programme for Research and Training in Tropical Diseases (TDR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate clinical outcomes and antibiotic prescription patterns following&#xD;
      the use of diagnostic algorithms, point of care rapid diagnostic tests, and behaviour change&#xD;
      interventions in cases of acute febrile illnesses in children, adolescents and adults&#xD;
      presenting at out patient clinics in lower and middle income countries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and rationale. 'Just-in-case' antibiotic prescribing practices is one of the&#xD;
      causes of inadequate management of 'acute febrile illnesses' and AMR in Low- and&#xD;
      Middle-income Countries (LMICs). At the same time, some people who would require antibiotic&#xD;
      treatment do not get it. An improvement in case management and prescription practice might&#xD;
      lead to a decrease in morbidity and mortality. Success will mean making significant steps&#xD;
      toward achieving the dual goal of improving UHC and tackling AMR.&#xD;
&#xD;
      The PICO question addressed is:&#xD;
&#xD;
        1. Population; patients (children/ adolescent and adult) presenting to outpatient clinics /&#xD;
           peripheral health centres in LMICs with acute febrile illness / Respiratory Tract&#xD;
           Infection&#xD;
&#xD;
        2. Intervention; combining available diagnostic tests, diagnostic aids/algorithms, clinic&#xD;
           process flow and, training and communication&#xD;
&#xD;
        3. Control; Compared to current practice&#xD;
&#xD;
        4. Outcome; can we improve management of acute febrile illnesses and better target the use&#xD;
           of antibiotics / reduce unnecessary antibiotic prescriptions as appropriate and feasible&#xD;
           Primary objective(s) To evaluate the impact of a package of interventions (point of care&#xD;
           [PoC] tests, clinical algorithm, clinic process flow, training and communication tools)&#xD;
           on clinical outcomes and antibiotic prescriptions, with standard-of-care practices, in&#xD;
           children and adolescents presenting with acute febrile illnesses (defined as fever with&#xD;
           no focus or Respiratory Tract Infection lasting for no more than 7 days), at outpatient&#xD;
           clinics Secondary objective(s)&#xD;
&#xD;
      1. To improve the management of acute febrile illness 2. To promote rational and targeted use&#xD;
      of antibiotics for acute febrile illness 3. To determine the aetiology of fever in patients&#xD;
      presenting to outpatient facilities using available PoC diagnostic tests 4. To study the&#xD;
      safety and feasibility of a package of interventions compared to current practice of care 5.&#xD;
      To assess the effectiveness of training and communication tools to adherence to the&#xD;
      prescribed treatment Primary endpoints (outcomes) 1. Proportion of outpatient cases of acute&#xD;
      febrile illness with favourable outcome (defined as being alive and asymptomatic).&#xD;
&#xD;
      2. antibiotic prescriptions rates for acute febrile illness in the clinic Secondary endpoints&#xD;
      (outcomes) 1. Duration of time spent in the clinic 2. Proportion of patients treated for&#xD;
      specific bacterial infection 3. Proportion of patients with disease specific diagnosis&#xD;
      identified by PoC tests 4. Frequency of serious adverse event (SAE) within 7 days of&#xD;
      recruitment 5. Frequency of unscheduled (unplanned) visit within 7 days of recruitment 6.&#xD;
      Training and communication package uptake 7. Proportion of patients prescribed antibiotic at&#xD;
      clinic who reported adherence to prescription on day 7 8. Proportion of patients who were not&#xD;
      prescribed antibiotics at clinic who received antibiotics elsewhere between day 0 and day 7&#xD;
      9. Behaviour Change Intervention Recommendations Trial design A multi-centre, open label, two&#xD;
      arm, randomized-controlled trial Trial sites/setting This study will be conducted in&#xD;
      outpatient departments and primary care clinics in Burkina Faso, Ghana, India, Myanmar, Nepal&#xD;
      and Uganda.&#xD;
&#xD;
      Trial population . The study population will consist of children, adolescents and adults&#xD;
      presenting to the health care facility, or provider, with acute fever or history of fever&#xD;
&#xD;
      Sample Size Approx. 10,000&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of acute febrile cases with favorable clinical outcomes at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Favorable defined as being alive and asymptomatic.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibiotic prescription rates in acute fever cases</measure>
    <time_frame>Day 0</time_frame>
    <description>Proportion of antibiotic prescriptions for acute febrile illness in the clinic</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with acute fever Diagnoses identified by point of care tests.</measure>
    <time_frame>Day 0</time_frame>
    <description>Proportion of patients with disease specific diagnosis identified by PoC tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 7</time_frame>
    <description>Frequency of adverse events within 7 days of recruitment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in the clinic</measure>
    <time_frame>Day 0</time_frame>
    <description>Time spent in the clinic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of study participants who adhered to antibiotic prescriptions</measure>
    <time_frame>Day 7</time_frame>
    <description>Adherence to antibiotic prescriptions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Acute Febrile Illness</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diagnostic algorithm( paper and electronic) utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change training for healthcare workers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care practices for acute febrile illness</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic algorithm+Point of care rapid diagnostic tests+ Behavior change ( assessed together as a single package of interventions)</intervention_name>
    <description>Diagnostic algorithm utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change intervention for healthcare workers</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with fever with no focus/RTI:&#xD;
&#xD;
               -  Children (6 months to &lt;12 years) and adolescents (12 years to less than 18 years&#xD;
                  old) of both sexes .&#xD;
&#xD;
               -  Presenting with an acute febrile illness defined as temperature of &gt;37.5°C or&#xD;
                  history of fever within the last 7 days with no focus or suspected RTI.&#xD;
&#xD;
               -  Parent/guardian providing written informed consent for their children if less&#xD;
                  than 18 years of age.&#xD;
&#xD;
               -  Obtain assent for adolescent between 12 and less than 18 years old&#xD;
&#xD;
               -  Willing to provide blood and other samples and adhere to study procedures&#xD;
                  explained in the consent forms following the protocol.&#xD;
&#xD;
               -  Available and willing to return for follow-up visit at the health facility on day&#xD;
                  7 (+/- 2 days).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  o Children and adolescents from 6 months to less than 18 years old presenting with&#xD;
             chronic febrile illness (fever lasting more than 7 days).&#xD;
&#xD;
               -  Patients with acute febrile illness outside the allowed age range for the site.&#xD;
&#xD;
               -  Severely ill patients requiring hospital admission or referral as assessed by the&#xD;
                  study clinicians.&#xD;
&#xD;
               -  Anyone refusing consent to the study or not able to attend the health centre for&#xD;
                  follow-up (adults, the children of parents/guardians, or adolescents who refuse&#xD;
                  or are missed when asking for consent).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piero Olliaro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Foundation for Innovative New Diagnostics (FIND)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piero Olliaro, MD</last_name>
    <phone>+41227100984</phone>
    <email>piero.olliaro@finddx.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olawale Salami, MD</last_name>
    <email>olawale.Salami@finddx.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRSS-DRCO/Clinical Research Unit of Nanoro (CRUN)</name>
      <address>
        <city>Nanoro</city>
        <zip>BP 218</zip>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halidou Tinto, PhD</last_name>
      <email>halidoutinto@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Francois Kiemde, PhD</last_name>
      <email>kiemdefrancois@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Halidou Tinto, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shai-Osudoku District Hospital</name>
      <address>
        <city>Accra</city>
        <state>Dodowa</state>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Baiden, MD</last_name>
      <email>rita_baiden@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jan Swathya Sahyog</name>
      <address>
        <city>Ganiyari</city>
        <state>Chhattisgarh</state>
        <zip>495112</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gajanan B Phutke, MBBS</last_name>
      <email>gajananphutke@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Naman Shah, MD</last_name>
      <phone>077532 44819</phone>
      <email>namankshah@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yogesh Jain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anju Kitaria, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Biswaroop Chatterjee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute of Cholera &amp; Enteric Diseases</name>
      <address>
        <city>Beliaghata</city>
        <state>Kolkata</state>
        <zip>700010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shanta Dutta, MD</last_name>
      <phone>033 2363 3373</phone>
      <email>shanta.niced@icmr.gov.in</email>
    </contact>
    <contact_backup>
      <last_name>Alok K Deb, PhD</last_name>
      <email>adeb02@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Agniva Majumad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sumanjo Kanungo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>R D Gardi Medical College</name>
      <address>
        <city>Ujjain</city>
        <state>Madhya Pradesh</state>
        <zip>456006</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pathak Ashish, MBBS</last_name>
      <phone>073682 61235</phone>
      <email>drashish.jpathak@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Manju Purohit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Post Graduate Insitute Medical Education and Research</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Neelam Taneja, MD</last_name>
      <phone>0172 274 7585</phone>
      <email>drneelampgi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Gajinder K Dewan, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arun K Bansal, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kawaljeet S Sandha, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruby Jain, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Patan Academy of Health Sciences</name>
      <address>
        <city>Lalitpur</city>
        <state>Lagankhel</state>
        <zip>44700</zip>
        <country>Nepal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Buddha Basnyat, MD</last_name>
      <email>buddhabasnyat@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Abhishek Giri, MD</last_name>
      <email>giriabhishek@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Buddha Basnyat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abhishek Giri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Disease research collaboration</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Kapisi, MD</last_name>
      <email>kapisij@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Heidi hopkins, MD</last_name>
      <email>hhopkins@lshtm.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>James Kapisi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heidi Hopkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Ghana</country>
    <country>India</country>
    <country>Nepal</country>
    <country>Uganda</country>
  </location_countries>
  <removed_countries>
    <country>Myanmar</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>to be discussed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

